Biogen’s Alzheimer’s Drug Could be Expensive Biogen (NASDAQ: BIIB) could price its Alzheimer’s drug, Lecanemab, developed along with Essai as high as $20,000 every year, Barron’s reported on Friday, citing data Read more
Tag: Biogen
Biogen shares jump 4.7% premarket on hopes for its Alzheimer’s treatment lecanemab
Biogen Inc. shares BIIB, -0.43% rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer’s disease failed to meet its main Read more
Biogen and Eisai make plans to take another Alzheimer’s drug to the FDA
Biogen Inc. BIIB, -1.93% and Eisai Co. Ltd. 4523, +3.57% are getting closer to a possible approval of their new treatment for Alzheimer’s disease, with plans to submit the drug Read more
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer’s drug success
Next stop regulatory approval. That was the view of analysts at Mizuho Securities, who late Tuesday lifted shares of Biogen Inc. BIIB, +1.04% to buy from neutral after the pharmaceutical Read more
Eisai shares indicated sharply higher after trial of experimental drug slows Alzheimer’s progression
Eisai Co. shares were indicated sharply higher Wednesday morning after the Japanese drug maker and Biogen Inc. said their experimental Alzheimer’s disease drug significantly slowed progression of the disease in Read more
Alzheimer’s drug from Eisai, Biogen shows promise in large trial
Eisai Co. 4523, +0.89% and Biogen Inc. BIIB, +1.04% said their experimental Alzheimer’s disease drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects for approval. The pharmaceutical companies Read more